The latest international news, analysis and features on the HIV epidemic from Avert. Share your views and expertise with your peers in the comments box below the articles.
Dolutegravir’s first bump in the road to global roll-out begs larger questions around women’s rights and access to contraceptives at the International AIDS Conference (AIDS 2018).
Interim clinical trial results offer hope to people living with hepatitis C who stand to benefit from reduced price treatment, including the 2.3 million people who have HIV co-infection.
The 2020 goal of reaching 120 million additional girls and young women with modern contraceptives is likely to be missed, despite millions of new users.
As HIV drug resistance increases in low- and middle-income countries, getting people onto antiretroviral treatment means little in the long run if treatment programming is not also strengthened.
The President’s Emergency Plan for AIDS Relief (PEPFAR) is to accelerate efforts in just 13 countries under its news strategy. But critics say this narrowed focus could lead to a resurgence of the HIV epidemic.
A BMJ international panel made up of women living with HIV, specialist doctors, and general practitioners recommends non-tenofovir based treatment regimes for pregnant women living with HIV.
Savings would be ‘small and transient’ – raising significant ethical and efficacy concerns about the benefit of US budget cuts for HIV programming abroad.
A ground-breaking review provides stark evidence of the damage criminalisation has on preventing and treating HIV among people who inject drugs.
Long-lasting antiretroviral drugs injected monthly present a ‘remarkable milestone’ in treatment options for people living with HIV
In the era of treat all, renewed emphasis is needed on the 39% of people living with HIV who start treatment late who are at an increased risk of deaths and opportunistic infections.